Michael P O’Connor

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

High Impact

Post Doctoral Researcher

University of Arkansas

Also affiliated: University of Messina (2006); Roche (Switzerland) (2013); Cincinnati Children's Hospital Medical Center (1996–2022); Merck & Co., Inc., Rahway, NJ, USA (United States) (2013); Biogen (United States) (2013); Pennsylvania State University (2007); United States Food and Drug Administration (2013); University of Debrecen (1999); California Department of Food and Agriculture (1991); Center for Drug Evaluation and Research (2013); University College London Hospitals NHS Foundation Trust (2025); University of Wisconsin–Madison (1994); Royal College of Surgeons in Ireland (2022–2024); University of Liverpool (2007–2022); Netherlands Organisation for Applied Scientific Research (2013); Medical University of South Carolina (2004); University of Illinois Urbana-Champaign (1977); Merck KGaA, Darmstadt (Germany) (2013); Eli Lilly (United States) (2013); Duke University (2007); Pfizer (United States) (2013); Genentech (2013); Lund University (2007); University of Aberdeen (2022–2025); University of Washington (2013); Savannah River National Laboratory (1992); Australian Government (2003); Cork University Hospital (2010); Department of Health and Aged Care (2003); University of Bristol (2020); University of Chicago (1997–2024); University of Chicago Medical Center (2024); Bristol-Myers Squibb (United States) (2013); Chris O’Brien Lifehouse (2022); GlaxoSmithKline (United States) (2013–2018); BD Biosciences (United States) (2013); Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (1997); St. Finbarr's Hospital (2010); Purdue University Fort Wayne (1990); Conservation Science Partners (2007); Absorption Systems (United States) (2013); Sanofi (Germany) (2013); AstraZeneca (Sweden) (2013); Solvo Biotechnology (Hungary) (2013); Eisai (United States) (2013); Optivia Biotechnology (United States) (2013); Boehringer Ingelheim (United States) (2013); Simcyp (United Kingdom) (2013); Centre international de recherche sur le cancer (1999); Takeda Oncology (United States) (2013); University College London (2025); Arizona State University (2022); University of Baltimore (2007); University of Cincinnati (2004–2018); Drexel University (1992–2024); University of Pennsylvania (2007); Ludwig-Maximilians-Universität München (1997); University of California, Davis (1991); Newcastle University (2018); Grand Valley State University (2007)

43 h-index 165 pubs 8,627 cited

Upstream record may be merged OpenAlex, the source of these figures, lists 61 institutions in 11 countries for this author record — a pattern that usually means it combines several researchers with similar names. The totals above may include work by other people.

Research Areas

Biomedical Subjects

Links

ORCID Lab Website

OverviewAI-generated summary

Michael P. O’Connor's research has investigated mechanisms of cellular damage and inflammation, particularly in the context of sepsis and shock. His work has examined the role of peroxynitrite in activating poly(ADP-ribose) synthetase, leading to cellular energy depletion and cytotoxicity in macrophages and smooth muscle cells. This research has been explored in animal models, including rats, to understand endothelial dysfunction during endotoxic shock.

Further research has delved into the modulation of signal transduction pathways by specific ligands to reduce systemic inflammation in polymicrobial sepsis. O’Connor's publications also extend to broader ecological and biological topics, including the intestinal microbiota of various populations and species, thermoregulation in reptiles and dinosaurs, and the influence of environmental factors on gut bacterial communities. His work has also touched upon the variability of drug interactions in in vitro systems.

With a career marked by significant scholarly output, O’Connor has published 172 papers, accumulating over 8,700 citations and an h-index of 43, designating him as a highly cited researcher. He has collaborated with researchers at the University of Arkansas at Fayetteville, including Taylor Ping, Adam M. Siepielski, Wade A. Boys, and Tara L. Lanzer.

Metrics

h-index: 43
Publications: 165
Citations: 8,627

Positions

Post Doctoral Researcher publications 2025

University of Arkansas at Fayetteville Biological Sciences ORCID

Selected Publications

The reshaping of trade-offs under climate warming (2026)

Trends in Ecology & Evolution 1 citation DOI OpenAlex
Cheating death: selection on digestive physiology overcomes expected growth costs of antipredator defences (2025)

Journal of Evolutionary Biology DOI OpenAlex